Simvastatin Preserves Cardiac Function in Genetically Determined Cardiomyopathy

Journal of Cardiovascular Pharmacology

Volumn 43, Issue 3, 2004, Pages 454-461

  Abraham, Seena S ^a,c   Osorio, Juan C ^a   Homma, Shunichi ^a   Wang, Jie ^a   Thaker, Harshwardhan M ^a   Liao, James K ^a,b   Mital, Seema ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NONE   (United States)

Author keywords

Angiogenesis; Heart failure; Nitric oxide; Remodeling; Statins

Indexed keywords

CASPASE 3; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SIMVASTATIN; STATINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CAPILLARY DENSITY; CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; ECHOCARDIOGRAPHY; ENDOTHELIUM; ENZYME ACTIVITY; GENE MUTATION; HAMSTER; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; MALE; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; APOPTOSIS; CARDIOMYOPATHIES; CASPASE 3; CASPASES; CRICETINAE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IN SITU NICK-END LABELING; MALE; NITRIC OXIDE; SIMVASTATIN; VENTRICULAR FUNCTION, LEFT;

EID: 1442276972     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200403000-00018     Document Type: Article

References (34)

1. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Nat Acad Sci. 1998;95:8880-8885.
2. Lefer AM, Campbell B, Shin Y-K, et al. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation. 1999;100:178-184.
3. Pruefer D, Scalia R, Lefer AM. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol. 1999;19:2894-2900.
4. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995;96:60-68.
5. Treasure CB, Vita JA, Cox DA, et al. Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation. 1990;81:772-779.
6. Drexler H. Nitric oxide and coronary endothelial dysfunction in humans. Cardiovasc Res. 1999;43:572-579.
7. Smith CJ, Sun D, Hoegler C, et al. Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure. Circ Res. 1996;78:58-64.
8. Kuoppala A, Shiota N, Kokkonen JO, et al. Down-regulation of cardioprotective bradykinin type-2 receptors in the left ventricle of patients with end-stage heart failure. J Am Coll Cardiol. 2002;40:119-125.
9. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med. 1997;336:1131-1141.
10. Mital S, Barbone A, Addonizio LJ, et al. Endogenous endothelium-derived nitric oxide inhibits myocardial caspase activity: implications for treatment of end-stage heart failure. J Heart Lung Transplant. 2002;21:576-585.
11. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129-1135.
12. Mital S, Zhang X, Zhao G, et al. Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. Am J Physiol Heart Circ Physiol. 2000;279:H2649-H2657.
13. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1004-1010.
14. Bauersachs J, Galuppo P, Fraccarollo D, et al. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation. 2001;104:982-985.
15. Hayashidani S, Tsutsui H, Shiomi T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002;105:868-873.
16. Sakamoto A, Ono K, Abe M, et al. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, delta-sarcoglycan, in hamster: An animal model of disrupted dystrophin-associated (-glycoprotein" ) complex. PNAS. 1997;94:13873-13878.
17. Nigro V, Okazaki Y, Belsito A, et al. Identification of the Syrian hamster cardiomyopathy gene. Hum Mol Genet. 1997;6:601-607.
18. Crespo MJAP, Escobales N. Altered vascular function in early stages of heart failure in hamsters. J Card Fail. 1997;3:311-318.
19. Suehiro K, Takuma S, Cardinale C, et al. Assessment of segmental wall motion abnormalities using contrast two-dimensional echocardiography in awake mice. Am J Physiol Heart Circ Physiol. 2001;280:H1729-H1735.
20. Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108:1429-1437.
21. Nahrendorf M, Hu K, Hiller K-H, et al. Impact of hydroxymethylglutaryl coenzyme a reductase inhibition on left ventricular remodeling after myocardial infarction: An experimental serial cardiac magnetic resonance imaging study. J Am Coll Cardiol. 2002;40:1695-1700.
22. Borghi C, Prandin MG, Costa FV, et al. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol. 2000;35:549-555.
23. Tonolo G, Melis MG, Formato M, et al. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest. 2000;30:980-987.
24. Weiland U, Haendeler J, Ihling C, et al. Inhibition of endogenous nitric oxide synthase potentiates ischemia-reperfusion-induced myocardial apoptosis via a caspase-3 dependent pathway. Cardiovasc Res. 2000;45:671-678.
25. Rossig L, Fichtlscherer B, Breitschopf K, et al. Nitric oxide inhibits Caspase-3 by S-Nitrosation in vivo. J Biol Chem. 1999;274:6823-6826.
26. Liu PP, Mak S. Potential role of the microvasculature in progression of heart failure. Am J Cardiol. 1999;84:23L-26L.
27. Taniyama Y, Morishita R, Aoki M, et al. Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy. Hypertension. 2002;40:47-53.
28. Chen JZZ, Li Y, Wang Y, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol. 2003;53:743-751.
29. Urbich C, Dernbach E, Zeiher AM, et al. Double-edged role of statins in angiogenesis signaling. Circ Res. 2002;90:737-744.
30. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998;273:24266-24271.
31. Kjekshus J. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 1995;76:64C-68C.
32. Kjekshus J, Pedersen TR, Olsson AG, et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997;3:249-254.
33. Mital S, Magneson A, Loke KE, et al. Simvastatin acts synergistically with ACE inhibitors or amlodipine to decrease oxygen consumption in rat hearts. J Cardiovasc Pharmacol. 2000;36:248-254.
34. Marz W Sr, Muller HM, Wieland H, et al. Effects of lovastatin and pravastatin on the survival of hamsters with inherited cardiomyopathy. J Cardiovasc Pharmacol Ther. 2000;5:275-279.